Advertisement

Click here for more guidelines.
2012 ACCF/ AATS/ SCAI/ STS Expert Consensus Document on Transcatheter Aortic Valve Replacement
ACCF/ SCAI/ STS/ AATS/ AHA/ ASNC/ HFSA/ SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update
2012 ACCF/ AHA/ ACR/ SCAI/ SIR/ STS/ SVM/ SVN Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease

 
About JACC CME
Policy on Privacy and Confidentiality
Disclosures
Important Information
 

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME
 
 

Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions
 
 

About the Journal
Editorial Board & Staff
 
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 48:1742-1750, doi:10.1016/j.jacc.2006.06.065 (Published online 16 October 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.06.065v1
48/9/1742    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (196)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hochholzer, W.
Right arrow Articles by Neumann, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hochholzer, W.
Right arrow Articles by Neumann, F.-J.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement

Willibald Hochholzer, MD*, Dietmar Trenk, PhD*, Hans-Peter Bestehorn, MD*, Benjamin Fischer*, Christian M. Valina, MD*, Miroslaw Ferenc, MD*, Michael Gick, MD*, Angelika Caputo, PhD{dagger}, Heinz Joachim Büttner, MD* and Franz-Josef Neumann, MD*,*

* Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
{dagger} Institut für Medizinische Biometrie und Medizinische Informatik, University of Freiburg, Freiburg, Germany.

Manuscript received December 8, 2005; revised manuscript received May 30, 2006, accepted June 6, 2006.

* Reprint requests and correspondence: Dr. Franz-Josef Neumann, Herz-Zentrum Bad Krozingen, Suedring 15, 79189 Bad Krozingen, Germany. (Email: franz-josef.neumann{at}herzzentrum.de).

OBJECTIVES: Our prospective study tested the hypothesis that the 30-day clinical outcome of elective percutaneous catheter intervention (PCI) differs between strata defined by quartiles of platelet aggregation after loading with 600 mg clopidogrel.

BACKGROUND: Platelet responses after loading with clopidogrel are highly variable. The impact of this variability on the peri-interventional risk of patients undergoing PCI has not been investigated prospectively.

METHODS: Our study included 802 consecutive patients undergoing elective coronary stent placement. Before PCI, patients received a loading dose of 600 mg clopidogrel followed by 75 mg daily. Primary end point was the 30-day composite of death, myocardial infarction, and target lesion revascularization (major adverse cardiac events [MACE]). Platelet aggregation was assessed immediately before PCI by optical aggregometry (5 µmol/l adenosine diphosphate).

RESULTS: During 30-day follow-up, 15 patients (1.9%) incurred MACE (3 deaths, 8 myocardial infarctions, 8 target lesion revascularizations). Quartiles of platelet aggregation were <4%, 4% to 14%, 15% to 32%, and >32%. Thirty-day MACE differed significantly (p = 0.034) between quartiles of platelet aggregation. It was 0.5% in the first quartile, 0.5% in the second, 3.1% in the third, and 3.5% in the fourth. Platelet aggregation above the median carried a 6.7-fold risk (95% confidence interval 1.52 to 29.41; p = 0.003) of 30-day MACE. Multivariable logistic regression analysis, including pertinent covariables, confirmed platelet aggregation as a significant independent predictor of 30-day MACE (adjusted odds ratio per 10% increase in platelet aggregation 1.32, 95% confidence interval 1.04 to 1.61; p = 0.026).

CONCLUSIONS: The level of platelet aggregation immediately before elective coronary stenting in patients pre-treated with a high loading dose of clopidogrel is correlated with early outcome after the procedure.

Abbreviations and Acronyms
  ADP = adenosine diphosphate
  AHA/ACC = American Heart Association/American College of Cardiology
  EXCELSIOR = Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate
  GP = glycoprotein
  MACE = major adverse cardiac event
  MI = myocardial infarction
  PCI = percutaneous catheter intervention
  TIMI = Thrombolysis In Myocardial Infarction


Related Articles

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2006 48: A41-A42. [Full Text] [PDF]

Platelet Function Assessment to Predict Outcomes After Coronary Interventions: Hype or Hope?
Fernando Alfonso and Dominick J. Angiolillo
J. Am. Coll. Cardiol. 2006 48: 1751-1754. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Journal of NeuroInterventional SurgeryHome page
T. M. Leslie-Mazwi, R. V. Chandra, D. C. Oh, and R. G. Nogueira
Novel use of prasugrel for intracranial stent thrombosis
JNIS, December 1, 2011; 3(4): 358 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
E. M. deGoma, G. Rivera, S. M. Lilly, M. H. U. Usman, and E. R. Mohler III
Personalized vascular medicine: Individualizing drug therapy
Vascular Medicine, October 1, 2011; 16(5): 391 - 404.
[Abstract] [PDF]

Home page
 Circ Cardiovasc IntervHome page
J.-S. Hulot, J.-P. Collet, G. Cayla, J. Silvain, F. Allanic, A. Bellemain-Appaix, S. A. Scott, and G. Montalescot
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients
Circ Cardiovasc Interv, October 1, 2011; 4(5): 422 - 428.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. J. Price, D. J. Angiolillo, P. S. Teirstein, E. Lillie, S. V. Manoukian, P. B. Berger, J.-F. Tanguay, C. P. Cannon, and E. J. Topol
Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial
Circulation, September 6, 2011; 124(10): 1132 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc GenetHome page
D. Trenk, W. Hochholzer, M. F. Fromm, O. Zolk, C. M. Valina, C. Stratz, and F.-J. Neumann
Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
Circ Cardiovasc Genet, August 1, 2011; 4(4): 429 - 436.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N. J. Breet, J. W. van Werkum, H. J. Bouman, J. C. Kelder, A. M. Harmsze, C. M. Hackeng, and J. M. ten Berg
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
Heart, June 15, 2011; 97(12): 983 - 990.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
W. Hochholzer, S. D. Wiviott, E. M. Antman, C. F. Contant, J. Guo, R. P. Giugliano, A. J. Dalby, G. Montalescot, and E. Braunwald
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)
Circulation, June 14, 2011; 123(23): 2681 - 2689.
[Abstract] [Full Text] [PDF]

Home page
 Journal of NeuroInterventional SurgeryHome page
D. Drazin, A. Choulakian, M. Nuno, P. Kornbluth, and M. J. Alexander
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting
JNIS, June 1, 2011; 3(2): 177 - 181.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Htun, S. Fateh-Moghadam, C. Bischofs, W. Banya, K. Muller, B. Bigalke, K. Stellos, A. E. May, M. Flather, M. Gawaz, et al.
Low Responsiveness to Clopidogrel Increases Risk among CKD Patients Undergoing Coronary Intervention
J. Am. Soc. Nephrol., April 1, 2011; 22(4): 627 - 633.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. J. Price, P. B. Berger, P. S. Teirstein, J.-F. Tanguay, D. J. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K. N. Garratt, O. F. Bertrand, et al.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial
JAMA, March 16, 2011; 305(11): 1097 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, and G. Di Sciascio
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation: Results of the ARMYDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Randomized Study
J. Am. Coll. Cardiol., February 15, 2011; 57(7): 771 - 778.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. M. Goodwin, A. R. Desilets, and K. C. Willett
Thienopyridines in Acute Coronary Syndrome
Ann. Pharmacother., February 1, 2011; 45(2): 207 - 217.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
O. Morel, S. El Ghannudi, L. Jesel, B. Radulescu, N. Meyer, M.-L. Wiesel, S. Caillard, U. Campia, B. Moulin, C. Gachet, et al.
Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel
J. Am. Coll. Cardiol., January 25, 2011; 57(4): 399 - 408.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
M. Tran, J. Tafreshi, and R. G. Pai
Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2010; 15(4): 326 - 337.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
S. D. Wiviott and J. L. Mega
Another Step on the Road to Tailored Antiplatelet Therapy
J. Am. Coll. Cardiol., November 9, 2010; 56(20): 1637 - 1638.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. F. Storey, D. J. Angiolillo, S. B. Patil, B. Desai, R. Ecob, S. Husted, H. Emanuelsson, C. P. Cannon, R. C. Becker, and L. Wallentin
Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
J. Am. Coll. Cardiol., October 26, 2010; 56(18): 1456 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
S.-J. Hwang, Y.-H. Jeong, I.-S. Kim, K.-S. Park, M.-K. Kang, J.-S. Koh, J. R. Park, Y. Park, E.-H. Koh, C. H. Kwak, et al.
Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
Circ Cardiovasc Interv, October 1, 2010; 3(5): 450 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
J. L. Ferreiro, M. Ueno, D. Capodanno, B. Desai, K. Dharmashankar, A. Darlington, R. K. Charlton, T. A. Bass, and D. J. Angiolillo
Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake: Results of a Prospective Randomized Crossover Study
Circ Cardiovasc Interv, October 1, 2010; 3(5): 436 - 441.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. Bonello, U. S. Tantry, R. Marcucci, R. Blindt, D. J. Angiolillo, R. Becker, D. L. Bhatt, M. Cattaneo, J. P. Collet, T. Cuisset, et al.
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
J. Am. Coll. Cardiol., September 14, 2010; 56(12): 919 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
M. H. Buch, B. D. Prendergast, and R. F. Storey
Antiplatelet therapy and vascular disease: an update
Therapeutic Advances in Cardiovascular Disease, August 1, 2010; 4(4): 249 - 275.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
R. Wada, S. Rohatagi, D. Small, K. J. Winters, and D. E. Salazar
Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes
J. Clin. Pharmacol., August 1, 2010; 50(8): 904 - 913.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
D. S. Roffman
Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention
Am. J. Health Syst. Pharm., August 1, 2010; 67(15_Supplement_7): S18 - S24.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. D. Wiviott, E. M. Antman, and E. Braunwald
Prasugrel
Circulation, July 27, 2010; 122(4): 394 - 403.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
Y.-H. Jeong, I.-S. Kim, Y. Park, M.-K. Kang, J.-S. Koh, S.-J. Hwang, C. H. Kwak, and J.-Y. Hwang
Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study
J. Am. Coll. Cardiol. Intv., July 1, 2010; 3(7): 731 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
W. Hochholzer, D. Trenk, M. F. Fromm, C. M. Valina, C. Stratz, H. P. Bestehorn, H. J. Buttner, and F. J. Neumann
Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
J. Am. Coll. Cardiol., June 1, 2010; 55(22): 2427 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
M. J. Price, A. Kalyanasundaram, and P. B. Berger
The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention
Circ Cardiovasc Interv, June 1, 2010; 3(3): 277 - 283.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
S. E. Ghannudi, P. Ohlmann, N. Meyer, M.-L. Wiesel, B. Radulescu, M. Chauvin, P. Bareiss, C. Gachet, and O. Morel
Impact of P2Y 12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty: A Prospective Registry
J. Am. Coll. Cardiol. Intv., June 1, 2010; 3(6): 648 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Sibbing, N. von Beckerath, T. Morath, J. Stegherr, J. Mehilli, N. Sarafoff, S. Braun, S. Schulz, A. Schomig, and A. Kastrati
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
Eur. Heart J., May 2, 2010; 31(10): 1205 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Angiolillo, E. Bernardo, D. Capodanno, D. Vivas, M. Sabate, J. L. Ferreiro, M. Ueno, P. Jimenez-Quevedo, F. Alfonso, T. A. Bass, et al.
Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
J. Am. Coll. Cardiol., March 16, 2010; 55(11): 1139 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. J. Breet, J. W. van Werkum, H. J. Bouman, J. C. Kelder, H. J. T. Ruven, E. T. Bal, V. H. Deneer, A. M. Harmsze, J. A. S. van der Heyden, B. J. W. M. Rensing, et al.
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
JAMA, February 24, 2010; 303(8): 754 - 762.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Sibbing, J. Stegherr, S. Braun, J. Mehilli, S. Schulz, M. Seyfarth, A. Kastrati, N. von Beckerath, and A. Schomig
A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment
J. Am. Coll. Cardiol., February 9, 2010; 55(6): 558 - 565.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, J. Stegherr, T. Morath, A. Schomig, N. von Beckerath, and A. Kastrati
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Circulation, February 2, 2010; 121(4): 512 - 518.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C. W. Kopp
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition
Heart, February 1, 2010; 96(3): 186 - 189.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. A. Farid, A. Kurihara, and S. A. Wrighton
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
J. Clin. Pharmacol., February 1, 2010; 50(2): 126 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, A. Kilias, B. Bigalke, K. Stellos, M. Schwab, A. E. May, et al.
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
Eur. Heart J., January 1, 2010; 31(1): 59 - 66.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1438 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Psychosom. Med.Home page
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med, September 1, 2009; 71(7): 741 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C. S. Ernest II, M. A. Heathman, and R. E. Wrishko
Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis
J. Clin. Pharmacol., August 1, 2009; 49(8): 973 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. D. Michelson, A. L. Frelinger III, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, et al.
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
Eur. Heart J., July 2, 2009; 30(14): 1753 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother., July 1, 2009; 43(7): 1266 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D. J. Angiolillo, M. Sabate, M. Hamon, A. Repetto, et al.
Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study
Circulation, June 30, 2009; 119(25): 3215 - 3222.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation, May 19, 2009; 119(19): 2625 - 2632.
[Full Text] [PDF]

Home page
 CirculationHome page
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. L. Macias, E. Braunwald, et al.
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Circulation, May 19, 2009; 119(19): 2553 - 2560.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D. Tousoulis, A. Briasoulis, S. S Dhamrait, C. Antoniades, and C. Stefanadis
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Heart, May 1, 2009; 95(10): 850 - 858.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. F. Ford
Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?
J. Clin. Pharmacol., May 1, 2009; 49(5): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon, and M. S. Sabatine
Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1273 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J., April 2, 2009; 30(8): 916 - 922.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Y.-H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati, and N. von Beckerath
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 849 - 856.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Mahla, M. J. Antonino, U. S. Tantry, and P. A. Gurbel
Point-of-Care Platelet Function Analysis: Ready for Prime Time?
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 857 - 859.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, et al.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Eur. Heart J., February 2, 2009; 30(4): 426 - 435.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. M. Scott, R. M Norwood, and D. Parra
P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
Ann. Pharmacother., January 1, 2009; 43(1): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1968 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. A. Cairns and J. Eikelboom
The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1978 - 1980.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, J.-P. Mouret, L. Bali, P.-J. Moro, M. Lambert, M.-C. Alessi, and J. L. Bonnet
Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study
J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 649 - 653.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1128 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. O. Williams and J. D. Abbott
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Circulation, September 16, 2008; 118(12): 1219 - 1222.
[Full Text] [PDF]

Home page
 CirculationHome page
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al.
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study
Circulation, September 16, 2008; 118(12): 1225 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate, et al.
Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 734 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Trenk and F.-J. Neumann
Aspirin Resistance: An Underestimated Risk in Patients With Drug-Eluting Stents?
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 740 - 742.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: II. Perioperative Considerations and Management
Anesth. Analg., August 1, 2008; 107(2): 570 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al.
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Eur. Heart J., July 1, 2008; 29(13): 1635 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Widimsky, Z. Motovska, S. Simek, P. Kala, R. Pudil, F. Holm, R. Petr, D. Bilkova, H. Skalicka, P. Kuchynka, et al.
Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
Eur. Heart J., June 2, 2008; 29(12): 1495 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott, and N. von Beckerath
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Eur. Heart J., June 2, 2008; 29(12): 1504 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
Heart, June 1, 2008; 94(6): 743 - 747.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1925 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. A. Cairns and J. Eikelboom
Clopidogrel Resistance: More Grist for the Mill
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1935 - 1937.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D3 - D11.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
L. Wallentin
Dual antiplatelet therapy in the drug-eluting stent era
Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D38 - D44.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Eur. Heart J., April 2, 2008; 29(8): 992 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer
Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting
AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens: Results From the PREPAIR Randomized Study
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1066 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 701 - 707.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al.
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial
Circulation, December 18, 2007; 116(25): 2923 - 2932.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al.
Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al.
Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1132 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
G. J. Weerakkody, J. A. Jakubowski, J. T. Brandt, C. D. Payne, H. Naganuma, and K. J. Winters
Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 205 - 212.
[Abstract] [PDF]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement